Bibliography
- Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011;65(2):189-210
- Ishibashi T, Horisawa T, Tokuda K, Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010;334(1):171-81
- Horiguchi M, Huang M, Meltzer HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 2011;338(2):605-14
- Galici R, Boggs JD, Miller KL, Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity. Behav Pharmacol 2008;19(2):153-9
- Horiguchi M, Huang M, Meltzer HY. Interaction of mGlu/agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology (Berl) 2011;217(1):13-24
- Ishiyama T, Tokuda K, Ishibashi T, Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 2007;572(2-3):160-70
- Horisawa T, Ishibashi T, Nishikawa H, The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav Brain Res 2011;220(1):83-90
- Enomoto T, Ishibashi T, Tokuda K, Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 2008;186(2):197-207
- Lee KR, Chae YJ, Koo TS. Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. Xenobiotica 2011;41(12):1100-7
- Meltzer HY, Cucchiaro J, Silva R, Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry 2011;168(9):957-67
- Nakamura M, Ogasa M, Guarino J, Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(6):829-36
- Potkin SG, Ogasa M, Cucchiaro J, Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res 2011;132(2-3):101-7
- Loebel A, Cucchiaro J, Sarma K, Lurasidone in the Treatment of Acute Schizophrenia: A Double-Blind, Placebo-Controlled Trial (PEARL 3). 12-5-2010
- Harvey PD, Ogasa M, Cucchiaro J, Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res 2011;127(1-3):188-94